Dow Jones
36 245,50 +294,60 (+0,82 %) Nasdaq
14 305,03 +78,83 (+0,55 %) Nikkei 225
33 190,37 -241,14 (-0,72 %) EUR/USD
1,0884 -0,0001 (-0,01 %) HANG SENG
16 794,03 -36,27 (-0,22 %) Bitcoin EUR
37 305,84 +1 066,08 (+2,94 %)
MRK Apr 2024 80.000 call
| Clôture précédente | 22,58 |
| Ouverture | 23,88 |
| Offre | 23,55 |
| Vente | 24,60 |
| Prix d’exercice | 80,00 |
| Date d’expiration | 2024-04-19 |
| Var. jour | 23,85 - 24,10 |
| Gamme de contrats | S.O. |
| Volume | |
| Position de place | 94 |
ACCESSWIREMRNA-4157/V940, an Investigational Personalized MRNA Cancer Vaccine, in Combination With Keytruda(R) (Pembrolizumab), Receives Prime Scheme Designation From the European Medicines Agency for Adjuvant Treatment of Patients With High-Risk Stage III/IV Melanoma Following Complete Resection
Moderna, Inc. (NASDAQ:MRNA), a biotechnology company pioneering messenger RNA (mRNA) therapeutics and vaccines, and Merck (NYSE:MRK), known as MSD outside of the United States and Canada, today announced that mRNA-4157/V940, an investigational personalized mRNA cancer vaccine, in combination with KEYTRUDA, Merck's anti-PD-1 therapy, has been granted Priority Medicines (PRIME) scheme designation by the European Medicines Agency (EMA) for the adjuvant
- ACCESSWIRE
Moderna and Merck Announce mRNA-4157/V940, an Investigational Personalized mRNA Cancer Vaccine, in Combination with KEYTRUDA(R) (pembrolizumab), Met Primary Efficacy Endpoint in Phase 2b KEYNOTE-942 Trial
Moderna, Inc. (NASDAQ:MRNA), a biotechnology company pioneering messenger RNA (mRNA) therapeutics and vaccines, and Merck (NYSE:MRK), known as MSD outside of the United States and Canada, today announced that the Phase 2b KEYNOTE-942/mRNA-4157-P201 trial of mRNA-4157/V940, an investigational personalized mRNA cancer vaccine, in combination with KEYTRUDA®, Merck's anti-PD-1 therapy, demonstrated a statistically significant and clinically meaningful
